武汉永璨生物科技有限公司
+86-17702719238 sales@sun-shinechem.com

Linzagolix

编号: 20266
Cas号: 935283-04-8
纯度: ≧98.0%

Linzagolix 是一种新型的口服 GnRH 受体拮抗剂,可有效治疗子宫内膜异位症相关的疼痛,同时减轻骨矿物质密度损失和其他通常与目前批准的治疗相关的不良反应。

仅供研究使用。 我们不向患者出售。

化学信息

名称Linzagolix
Iupac 化学名称3-{5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl}-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid
同义词Linzagolix ; OBE2109 ; OBE 2109 ; OBE-2109 ; KLH-2109 ; KLH 2109 ; KLH2109 ;
英文同义词Linzagolix ; OBE2109 ; OBE 2109 ; OBE-2109 ; KLH-2109 ; KLH 2109 ; KLH2109 ;
分子式C22H15F3N2O7S
分子量508.42
SmileO=C(C1=C(C(N2C3=CC(OCC4=C(OC)C=CC(F)=C4F)=C(OC)C=C3F)=O)C(NC2=O)=CS1)O
InChiKeyBMAAMIIYNNPHAB-UHFFFAOYSA-N
InChiInChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
Cas号935283-04-8
相关CAS号935283-04-8 (free) ; 1321816-57-2 (choline)

订购信息

包装价格库存纯度备货期
大货询价询价询价
Request Bulk Quote Download MSDS 电话 : +86-177 0271 9238   Email : sales@sun-shinechem.com
外观性状类白色固体
纯度≧98.0%
存储0-4 ℃ 可短期保存(两周);- 20 ℃ 可长期保存。
可溶性溶解于DMSO。
处理方式Refer to MSDS operation
运输条件可在室温下运输。
海关编码2934200090
Coming soon.
TargetsGnRH receptor antagonist
Mechanism
Cell study
Animal study
Clinical study

1: Borini A, Coticchio G. Gonadotropin-releasing hormone antagonist linzagolix: possible treatment for assisted reproduction patients presenting with adenomyosis and endometriosis? Fertil Steril. 2020 Sep;114(3):517-518. doi: 10.1016/j.fertnstert.2020.06.003. Epub 2020 Aug 3. PMID: 32762949.

2: Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020 Sep;114(3):640-645. doi: 10.1016/j.fertnstert.2020.04.017. Epub 2020 Jun 2. PMID: 32507315.

3: Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44-55. doi: 10.1016/j.fertnstert.2020.02.114. Epub 2020 Jun 4. PMID: 32505383.

4: Pohl O, Marchand L, Bell D, Gotteland JP. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020 Apr;27(4):988-995. doi: 10.1007/s43032-020-00172-z. Epub 2020 Feb 25. PMID: 32100275.


化学结构

20266 - Linzagolix | CAS 935283-04-8

快速订购

Change